Dillione Janet 4

4 · CorMedix Inc. · Filed Nov 26, 2025

Form 4

Period: 2025-11-24

Director

Transactions

Exercise/Conversion
Common Stock
2025-11-24$2.85/sh+8,000$22,800→ 56,473 total
Exercise/Conversion
Common Stock
2025-11-24$4.03/sh+7,790$31,394→ 64,263 total
Exercise/Conversion
Common Stock
2025-11-24$4.43/sh+4,876$21,601→ 69,139 total
Exercise/Conversion
Common Stock
2025-11-24$3.55/sh+5,677$20,153→ 74,816 total
Sale
Common Stock
2025-11-24$9.93/sh−26,343$261,586→ 48,473 total
Exercise/Conversion
Stock Option (Right to Buy Common Stock)
2025-11-24−8,000→ 0 total
Exercise: $2.85Exp: 2028-02-16→ Common Stock (8,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy Common Stock)
2025-11-24−7,790→ 12,210 total
Exercise: $4.03Exp: 2032-02-22→ Common Stock (7,790 underlying)
Exercise/Conversion
Stock Option (Right to Buy Common Stock)
2025-11-24−4,876→ 15,124 total
Exercise: $4.43Exp: 2033-01-14→ Common Stock (4,876 underlying)
Exercise/Conversion
Stock Option (Right to Buy Common Stock)
2025-11-24−5,677→ 24,323 total
Exercise: $3.55Exp: 2034-03-05→ Common Stock (5,677 underlying)

Footnotes (5)

[F1]This transaction was executed in multiple trades at prices ranging from $9.72 to $10.00, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
[F2]These options were granted on 02/16/2018. These options are fully vested.
[F3]These options were granted on 02/22/2022. These options are fully vested.
[F4]These options were granted on 01/14/2023. These options are fully vested.
[F5]These options were granted on 03/05/2024. These options are fully vested.

Documents

1 file